Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sierra Oncology Inc. (SRRA)

11.02   0.35 (3.28%) 10-01 16:03
Open: 10.6498 Pre. Close: 10.67
High: 11.02 Low: 10.6498
Volume: 1,114 Market Cap: 115M
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.314 - 11.369 11.369 - 11.424
Low: 10.424 - 10.491 10.491 - 10.556
Close: 10.547 - 10.652 10.652 - 10.756

Technical analysis

as of: 2020-10-01 3:39:31 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 15.02     One year: 16.73
Support: Support1: 10.50    Support2: 8.74
Resistance: Resistance1: 12.86    Resistance2: 14.32
Pivot: 11.17
Moving Average: MA(5): 10.82     MA(20): 11.37
MA(100): 12.49     MA(250): 178.05
MACD: MACD(12,26): -0.35     Signal(9): -0.29
Stochastic oscillator: %K(14,3): 12.59     %D(3): 12.44
RSI: RSI(14): 42.44
52-week: High: 880.00  Low: 8.55  Change(%): -98.3
Average Vol(K): 3-Month: 2270  10-Days: 1227

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
SRRA has closed above bottom band by 30.0%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 14 Sep 2020
Sierra to Present at September Investor Conferences - PRNewswire

Fri, 04 Sep 2020
What You Need To Know About Sierra Oncology, Inc.'s (NASDAQ:SRRA) Investor Composition - Yahoo Finance

Thu, 20 Aug 2020
Sierra Oncology Inc (SRRA) Stock: What Does the Chart Say? - InvestorsObserver

Thu, 20 Aug 2020
Chief Development Officer Barbara Klencke Just Bought 162% More Shares In Sierra Oncology, Inc. (NASDAQ:SRRA) - Simply Wall St

Tue, 28 Jul 2020
Sierra Oncology Appoints Christina Thomson as General Counsel - GlobeNewswire

Thu, 18 Jun 2020
Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 10
Shares Float (M) 3
% Held by Insiders 3.42
% Held by Institutions 57.14
Shares Short (K) 7
Shares Short P. Month (K) 4

Stock Financials

EPS -15.270
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 11.220
Profit Margin
Operating Margin
Return on Assets (ttm) -40.3
Return on Equity (ttm) -116.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -6.500
Qtrly Earnings Growth
Operating Cash Flow (M) -48
Levered Free Cash Flow (M) -32

Stock Valuations

PE Ratio -0.71
PEG Ratio
Price to Book value 0.96
Price to Sales
Price to Cash Flow -2.35

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.